欧洲血液与骨髓移植学会（EBMT）作为全球移植与细胞治疗领域的领军学术组织，长期以来致力于推动临床研究、优化患者管理并促进国际协作。在细胞与基因疗法迅猛发展的今天，EBMT正迎来新的历史机遇。会议期间，现任EBMT主席、法国里尔大学附属医院Ibrahim Yakoub-Agha教授系统阐述了学会发展愿景与行动路径，以期为全球同行提供借鉴与启发。
Ibrahim Yakoub-Agha教授：作为EBMT新任主席，我的后续工作将聚焦于以下几项核心优先事项。首要任务是进一步加强学会的登记系统。该体系本身已具备良好基础，需持续强化其功能，使其不仅为研究人员开展研究提供支持，也能协助各成员中心深入理解自身的临床实践与成果。
第二项优先任务是深化EBMT与世界各地区，特别是中国、亚洲、非洲及南美洲之间的合作关系。此举具有重要意义。目前，学会已设立全球委员会，其下属各分委员会负责人即来自上述地区。未来需通过共同努力，探索EBMT能为各国同仁提供的支持，以及各方能为学会发展带来的价值，从而推动EBMT切实成为移植与细胞治疗领域的全球引领性学术组织。此外，在学会自身建设层面，优化组织架构、简化工作流程以提升运行效率，也是一项重要工作。
在CAR-T细胞疗法的临床推广方面，相关工作已于数年前在欧洲及全球范围内陆续展开。EBMT与欧洲血液学会（EHA）在相关指南制定与实践标准化方面发挥了关键作用，并已发表多篇关于CAR-T细胞潜在并发症及其患者管理的学术论文。约两年前起，学会开始致力于在学术层面推动CAR-T细胞生产工艺的标准化，协调质量控制流程，以保障产品生产质量。因此，就监管相关问题而言，实现患者管理规范与生产流程的统一，有助于增强欧洲乃至全球监管机构对该技术的信心，从而更积极地支持其在学术中心的推广应用。当然，商业化CAR-T细胞产品仍然不可或缺，这源于患者需求的持续增长及其在临床中的广泛应用。
全球委员会的建立，旨在广泛吸纳来自不同国家与地区的同仁共同参与。登记系统的目标不仅在于监测数据与产出成果，更旨在使其成为服务于各中心的实用工具：帮助中心评估自身实践，并基于自身患者结局与全球数据的比较，持续改进医疗质量。一切工作的根本宗旨，在于为患者提供最佳照护。疾病无国界，若能惠及全球患者，方为医学之真正愿景。尽管实现这一目标仍需努力，但这正是明确的前进方向。该登记系统也将在异基因移植及CAR-T细胞治疗等细胞治疗领域持续发挥重要作用。
As the President of the EBMT, several priorities will guide my tenure. The foremost involves enhancing the EBMT registry, which is already a robust tool. It is essential to further empower this resource, enabling researchers to conduct meaningful studies and supporting individual centers in better understanding and benchmarking their own clinical activities.
Another key priority is to strengthen EBMT’s relationships and collaborations with regions around the world, notably China, Asia, Africa, and South America. This is of great importance. We have established a Global Committee with subcommittee leaders from these regions, and we must work collectively to explore how EBMT can support colleagues in these countries and, in turn, how their insights and participation can contribute to EBMT’s growth. Through such partnership, EBMT can further solidify its role as the leading society in transplantation and cellular therapy. At an organizational level, additional priorities include streamlining the society’s structure and processes to improve overall efficiency.
Regarding CAR-T cell therapy implementation, EBMT—along with EHA—has played an instrumental role in developing guidelines and harmonizing clinical practices across Europe and beyond. Over the years, we have published extensively on CAR-T-related complications and patient management. More recently, over the past two years, efforts have expanded to harmonize academic-level CAR-T manufacturing processes, quality control standards, and production protocols to ensure excellence in therapeutic product preparation. In response to your question on regulation, harmonization in both patient management and production can provide regulatory agencies in Europe and worldwide with greater confidence, thereby encouraging broader adoption of this technology within academic centers. That said, commercially available CAR-T products remain essential given the rising patient numbers and their expanding use in clinical practice.
As noted, the Global Committee aims to engage colleagues from diverse countries and regions. The vision for the EBMT registry extends beyond data collection and research publication; it should serve as a practical tool for all centers to evaluate their own outcomes, compare practices internationally, and identify opportunities for improvement. Ultimately, our mission is to advance patient care. Disease knows no borders, and the ability to improve outcomes for patients worldwide represents a fundamental aspiration. While there is still progress to be made, this direction remains our clear path forward. The registry will continue to support these efforts in areas such as allogeneic transplantation and emerging cellular therapies like CAR-T.
总结
从现任主席的阐述中，我们可以清晰地看到EBMT未来发展的核心逻辑：以数据为基石，以协作为桥梁，以患者为中心。登记系统不再仅仅是科研数据的存储库，而是赋能各中心自我反思、持续改进的动态工具；全球合作不再停留于学术交流层面，而是通过构建包含中、亚、非、南美的实质性网络，实现经验共享与能力共建。尤为难能可贵的是，面对CAR-T等前沿疗法的快速迭代，学会主动将患者管理、生产工艺和质量控制纳入标准化框架，既为监管机构提供了科学依据，也为学术中心参与创新治疗开辟了道路。
这种“无国界”的医学理念，正是现代血液与细胞治疗领域最宝贵的精神财富。无论患者身处何方，其获得安全、有效、可及的治疗权利应当平等。EBMT的愿景提醒我们：技术的终极价值不在于发表多少论文或获得多少专利，而在于能否真正抵达每一位需要的患者身边。从欧洲到亚洲，从商业产品到学术生产，从登记数据到临床决策——唯有打破壁垒、携手前行，我们才能将“治愈”的希望播撒到世界的每一个角落。这不仅是EBMT的目标，也是全球医学共同体应当共同奔赴的方向。